Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The length is 4050 characters, which is relatively short but contains substantive financial data and analysis for the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and substantive financial data. It is not merely an announcement or a certification, but a summary report with financial figures and shareholder data. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2022
2022-08-22 Chinese
2022年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shenzhen Microchip Biotechnology Co., Ltd. during the first half of 2022. It includes specifics on the amount raised, usage of funds, balances, investment projects, changes in fund usage, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes financial figures and tables related to fundraising and fund deployment. The document is not a general annual or interim financial report but a specialized report focused on the management and use of raised capital. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (8667 characters) and content indicate it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-08-22 Chinese
关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotech Co., Ltd. about holding a 2022 semi-annual performance explanation meeting (业绩说明会). It specifies the meeting date, time, location, and participation details. The document states that the company will release its 2022 semi-annual report on August 23, and the meeting on August 24 is to explain the results and answer investor questions. The document itself does not contain financial statements or substantive financial data but is an announcement about an upcoming investor presentation related to the interim report. Given the document length (1403 characters) and content, it is not the interim report itself but an announcement of an investor presentation event focused on financial results. Therefore, the best classification is Investor Presentation (IP).
2022-08-16 Chinese
关于签订募集资金专户存储三方及四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the signing of tripartite and quadripartite supervision agreements for the special accounts holding funds raised from a convertible bond issuance. It details the amount raised, the opening of special accounts, the parties involved, and the terms of the supervision agreements. There are no financial statements or detailed financial performance data included. The document is primarily about the management and regulatory compliance of the raised funds, not a financial report or earnings release. It is also not a certification or a brief summary but a formal announcement of agreements related to capital raising and fund management. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4494 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2022-08-05 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司使用暂时闲置募集资金和自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities firm regarding the use of temporarily idle raised funds and own funds by Shenzhen Microchip Biotechnology Co., Ltd. for cash management. It references regulatory guidelines on the management and use of raised funds, details the amounts raised from IPO and convertible bonds, and outlines the cash management plan, investment products, risk controls, and approvals. The document is not a financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is a regulatory compliance and verification opinion related to the use of raised funds, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance-related disclosure.
2022-08-05 Chinese
第二届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Microchip Biotechnology Co., Ltd. It details the decisions made in their 12th meeting of the second Supervisory Board, including approval of proposals related to the use of convertible bond proceeds for project funding and cash management. The document is relatively short (1990 characters) and primarily serves as an official announcement of meeting resolutions rather than a full financial report or detailed management discussion. It references other announcements published on the Shanghai Stock Exchange website for more details. There are no financial statements or comprehensive financial data included. Therefore, this document fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-05 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.